Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Novo, Sanofi face off with new diabetes drugs

Rivals Novo Nordisk and Sanofi have won U.S. approval for new combination drugs to treat diabetes, sparking a fresh battle for sales in a fiercely competitive market.

Read More »

Novartis Buys U.S. Sickle Cell Drugmaker Selexys

Novartis exercised its option to acquire Selexys Pharmaceuticals based on the SUSTAIN Phase II clinical trial of SelG1, an anti-P-selectin antibody.

Read More »

Gilead Myelofibrosis Drug Flops in Phase III

Gilead Sciences announced top-line results from two Phase III clinical trials with mixed results for the Janus kinase (JAK) inhibitor momelotinib.

Read More »

Amgen, Novartis aim for big, crowded migraine market after new drug data

Episodic migraine sufferers reported fewer debilitating headaches per month after using Amgen and Novartis’ investigational drug erenumab, compared to trial participants who got a placebo.

Read More »

Puma Biotech Crashes After Diarrhea Risk is Linked to Breast Cancer Drug

Puma Biotechnology shares plummeted after the company disclosed patients taking its experimental breast cancer drug neratinib may require a second drug to prevent serious diarrhea.

Read More »

Pfizer wins EU approval for Ibrance as Novartis readies rival drug

Pfizer won approval from the European Union for its best-selling breast cancer drug Ibrance, making it the first medicine of its kind to reach the European market.

Read More »

Biotech, Pharma Stocks Jump after Trump Victory

The reality of a President-elect Donald Trump has been a shot in the arm for pharma and biotech leaders’ stock prices as they surged in U.S. and European markets.

Read More »

Adverse events in trial dent hopes for Roche hemophilia drug

Four patients have suffered serious adverse events in a clinical trial of an experimental hemophilia medicine from Roche, the Swiss group said, clouding prospects for its potential blockbuster product.

Read More »

Gilead Racks Up Clinical Failures in Q3 Report

Investors were not particularly happy with Gilead’s Q3 2016 report. In addition to sagging sales and revenue, it outlined a laundry list of failed clinical trials.

Read More »

Pfizer Abandons Cholesterol Drug Bococizumab

Pfizer has abandoned its PCSK9 inhibitor program to treat cholesterol. The company is ending its global development of all bococizumab SPIRE Phase III trials.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom